Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy

Figure 1

Overall survival curve based on platelet count at pretreatment, posttreatment, lymphocyte percentage, platelet-to-lymphocyte (%) ratio, and neutrophil-to-lymphocytes ratio (n=105). (a) Platelet count of more than 300,000/μL at pretreatment was associated with poor prognosis. The median survival was 423 days in the high platelet count group and 928 days in the low platelet count group (P = .018). (b) Platelet count of more than 300,000/μL at posttreatment was associated with poor prognosis. The median survival was 394 days in the high platelet count group and 791 days in the low platelet count group (P = .010). (c) Overall survival curve based on 3 groups. Group 1 was high platelet counts at pretreatment and posttreatment. Group 2 was a low platelet count at pretreatment with a high platelet count at posttreatment, or a high platelet count at pretreatment with a low platelet count at posttreatment. Group 3 was low platelet counts at pretreatment and posttreatment. The cutoff level for the platelet count was 300,000/μL. The median OS for the groups 1, 2, and 3 was 394, 426, and 953 days, respectively (P = .013). (d) Low lymphocyte percentage (>16%) was associated with poor prognosis. The median survival was 423 days in the low group and 958 days in the high group (P = .008). (e) High platelet-to-lymphocyte (%) ratio (>14,605) was associated with poor prognosis. The median survival was 426 days in the high ratio group and 953 days in the low ratio group (P = .021). (f) High neutrophil-to-lymphocytes ratio (>4.35) was associated with poor prognosis. The median survival was 461 days in the high ratio group and 953 days in the low ratio group (P = .010).

(a)

(b)

(c)

(d)

(e)

(f)